PE20040324A1 - Formulaciones liquidas de baja dosis de entecavir y uso - Google Patents

Formulaciones liquidas de baja dosis de entecavir y uso

Info

Publication number
PE20040324A1
PE20040324A1 PE2003000351A PE2003000351A PE20040324A1 PE 20040324 A1 PE20040324 A1 PE 20040324A1 PE 2003000351 A PE2003000351 A PE 2003000351A PE 2003000351 A PE2003000351 A PE 2003000351A PE 20040324 A1 PE20040324 A1 PE 20040324A1
Authority
PE
Peru
Prior art keywords
entecavir
liquid
formulated
composition
compositions
Prior art date
Application number
PE2003000351A
Other languages
English (en)
Inventor
Divyakant Desai
Danping Danping
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20040324A1 publication Critical patent/PE20040324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPOSICIONES FARMACEUTICAS LIQUIDAS QUE TIENEN UNA BAJA DOSIS DE ENTECAVIR PARA TRATAR INFECCIONES POR EL VIRUS DE HEPATITIS B COMO: a) UNA COMPOSICION LIQUIDA DE ENTECAVIR LISTA PARA USAR, FORMULADA PARA SER ESTABLE Y DE SABOR AGRADABLE, DONDE EL ENTECAVIR ESTA PRESENTE EN LA COMPOSICION EN UNA CANTIDAD DE ALREDEDOR DE 0.001% HASTA ALREDEDOR DE 20% P/V, b) UNA COMPOSICION LIQUIDA QUE ESTA FORMULADA A PARTIR DE UN POLVO PARA CONSTITUCION COMO UNA COMPOSICION LIQUIDA EN ELMOMENTO DE USO, QUE COMPRENDE ALREDEDOR DE 0.001% HASTA ALREDEDOR DE 20% PESO DE ENTECAVIR BASADO EN EL PESO TOTAL DE LA COMPOSICION EN POLVO.ESTAS COMPOSICIONES TIENEN POR LO MENOS UN COMPONENTE ADICIONAL SELECCIONADO DE UNO O MAS DE LOS SIGUIENTES: EDULCORANTE, CONSERVADOR, AGENTE SABORIZANTE, AGENTE DE SOLUCION AMORTIGUADORA AGENTE DE AJUSTE DE PH O COMBINACION DE ESTOS, TAMBIEN PUEDEN SER FORMULADAS EN COMBINACION CON OTROS AGENTES FARMACEUTICAMENTE ACTIVOS COMO DIDANOSINA, LAMIVUDINA, ABACAVIR, ADEFOVIR, ADEFOVIR DIPIVOXIL,FAMCICLOVIR, PROTEINAS INMUNOMODULADORAS DE HEPATITIS B ENTRE OTROS.TAMBIEN SE REFIERE A UN PROCESO PARA FORMULAR AMBAS COMPOSICIONES.
PE2003000351A 2002-04-08 2003-04-08 Formulaciones liquidas de baja dosis de entecavir y uso PE20040324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37067402P 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
PE20040324A1 true PE20040324A1 (es) 2004-05-29

Family

ID=29250568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000351A PE20040324A1 (es) 2002-04-08 2003-04-08 Formulaciones liquidas de baja dosis de entecavir y uso

Country Status (22)

Country Link
US (1) US20030190334A1 (es)
EP (1) EP1492510A4 (es)
JP (1) JP2005528389A (es)
KR (1) KR20040099403A (es)
CN (1) CN1319517C (es)
AR (1) AR039388A1 (es)
AU (1) AU2003226259A1 (es)
BR (1) BR0309057A (es)
CA (1) CA2481092A1 (es)
EA (1) EA008102B1 (es)
EC (1) ECSP045349A (es)
HR (1) HRP20040893A2 (es)
MX (1) MXPA04009735A (es)
MY (1) MY131488A (es)
NO (1) NO20044451L (es)
NZ (1) NZ535535A (es)
PE (1) PE20040324A1 (es)
PL (1) PL372322A1 (es)
RS (1) RS88404A (es)
TW (1) TWI275392B (es)
WO (1) WO2003086367A1 (es)
ZA (1) ZA200407672B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN1732944B (zh) * 2005-09-02 2013-05-08 海南中和药业有限公司 恩替卡韦分散片及其制备方法
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
CN101869569A (zh) * 2009-04-21 2010-10-27 李迪 即用型恩替卡韦组合物
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
CN102908312B (zh) * 2011-11-10 2014-06-04 陈小花 抗乙肝病毒液体组合物
US8517850B1 (en) * 2012-12-11 2013-08-27 Cobra Golf Incorporated Golf club grip with device housing
KR101462018B1 (ko) * 2013-04-01 2014-11-19 썬시스템즈(주) 엔테카비르 함유 구강 붕해형 필름제제
CN103301071A (zh) * 2013-06-03 2013-09-18 北京阜康仁生物制药科技有限公司 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法
BR112016002342A8 (pt) * 2013-08-06 2018-01-23 Dong Kook Pharm Co Ltd microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
MY185605A (en) * 2014-06-20 2021-05-25 Ctc Bio Inc Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CN104083374A (zh) * 2014-07-18 2014-10-08 石家庄创建医药科技有限公司 一种恩替卡韦口服液组合物
CN109984996B (zh) * 2018-01-02 2022-01-18 扬子江药业集团有限公司 恩替卡韦口服溶液及其制备方法
CN108434096A (zh) * 2018-06-20 2018-08-24 广州大光制药有限公司 一种恩替卡韦口服溶液及其制备方法
US20210259960A1 (en) * 2018-06-29 2021-08-26 The Doshisha Formulation containing emricasan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU760574B2 (en) * 1999-01-12 2003-05-15 Smithkline Beecham Biologicals (Sa) Novel treatment
MXPA02008359A (es) * 2000-02-29 2003-02-12 Squibb Bristol Myers Co Formulacion de entecavier de dosis baj y uso.
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
CN1658844A (zh) 2005-08-24
CA2481092A1 (en) 2003-10-23
KR20040099403A (ko) 2004-11-26
EP1492510A4 (en) 2006-01-11
EA008102B1 (ru) 2007-04-27
HRP20040893A2 (en) 2005-02-28
WO2003086367A1 (en) 2003-10-23
PL372322A1 (en) 2005-07-11
ECSP045349A (es) 2005-01-03
NZ535535A (en) 2006-09-29
TW200306840A (en) 2003-12-01
BR0309057A (pt) 2005-02-01
AR039388A1 (es) 2005-02-16
EP1492510A1 (en) 2005-01-05
US20030190334A1 (en) 2003-10-09
TWI275392B (en) 2007-03-11
NO20044451L (no) 2004-11-04
MY131488A (en) 2007-08-30
ZA200407672B (en) 2005-10-12
AU2003226259A1 (en) 2003-10-27
EA200401298A1 (ru) 2005-02-24
CN1319517C (zh) 2007-06-06
JP2005528389A (ja) 2005-09-22
MXPA04009735A (es) 2005-01-11
RS88404A (en) 2006-12-15

Similar Documents

Publication Publication Date Title
PE20040324A1 (es) Formulaciones liquidas de baja dosis de entecavir y uso
BRPI0412849A (pt) compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c
WO2006000922A3 (en) 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
UY27874A1 (es) Cster de 2' -c -netil- 3 ' -o-l-valina de ribofuranosilcitidina para el tratamiento de infecciones de flaviviridae.
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
HRP20110801T1 (hr) Tekući oblik fsh
SV1995000002A (es) Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
DE60019902D1 (de) Echinocandin pharmazeutische zusammensetzungen
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
BRPI0418115A (pt) formulação lìquida estável de hormÈnio de crescimento
ES2163631T3 (es) Un peptido mejorado, composicion inmunogenica y vacuna o preparacion medica, un procedimiento para inmunizar a los animales contra la hormona lhrh, analogos del peptido lhrh repetidos en tandem y su uso como vacuna.
ES2732892T3 (es) Composición de tratamiento de hongos en las uñas
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis
AR056017A1 (es) Formulaciones de vacuna animal, metodo para preparar una formulacion de vacuna y componente estabilizador de vacuna
AU3548901A (en) Veterinary compositions for the treatment of parasitic diseases
DE69006401D1 (de) Aerosolzusammensetzungen zur topischen Anwendung.
BR0313175A (pt) Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent
WO2004096197A8 (en) 5-aza-7-deazapurine nucleosides for treating flaviviridae

Legal Events

Date Code Title Description
FC Refusal